Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid secretion. It is available as oral tablets and granules, and as an intravenous (IV) formulation.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Treatment of pathological hypersecretory conditions, such as Zollinger-Ellison syndrome.
* Reduction of the risk of NSAID-associated gastric ulcers in patients at risk.
## Adult Dosing
* **Erosive Esophagitis (Healing):** 40 mg orally once daily for up to 8 weeks.
* **Erosive Esophagitis (Maintenance):** 40 mg orally once daily. For some patients, 20 mg orally once daily may suffice.
* **Pathological Hypersecretory Conditions:** Starting dose is 40 mg orally twice daily. Doses may be increased to 40 mg up to three times daily. Doses as high as 240 mg daily have been administered intravenously for prolonged periods.
* **NSAID-Associated Gastric Ulcer Prevention:** 40 mg orally once daily.
## Pediatric Dosing
* **GERD (including erosive esophagitis):**
* Children 5 to 11 years: 20 mg orally once daily for up to 8 weeks.
* Adolescents 12 to 17 years: 40 mg orally once daily for up to 8 weeks.
* Dosing in children younger than 5 years is not established for oral formulations. IV formulation is approved for children 5-16 years for short-term treatment of GERD.
## Dose Adjustments
* **Hepatic Impairment:** Maximum dose of 40 mg orally once daily.
* **Renal Impairment:** No dose adjustment is generally recommended.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
* Concomitant use with rilpivirine-containing products.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, dizziness, flatulence.
* **Serious:** Clostridium difficile-associated diarrhea, bone fracture (hip, wrist, spine), hypomagnesemia (can be severe and prolonged), vitamin B12 deficiency (long-term use), fundic gland polyps (long-term use).
## Key Drug Interactions
* **CYP2C19 substrates:** Pantoprazole inhibits CYP2C19. May increase concentrations of drugs metabolized by this enzyme (e.g., clopidogrel, voriconazole).
* **CYP3A4 substrates:** May affect absorption of drugs requiring gastric acid for absorption (e.g., ketoconazole, itraconazole, atazanavir, nelfinavir).
* **Methotrexate:** PPIs may increase methotrexate levels.
* **Rilpivirine:** Contraindicated due to increased risk of virologic failure.
* **Sucralfate:** May decrease absorption of pantoprazole. Separate administration by at least 30 minutes.
## Monitoring
* Monitor for signs and symptoms of Clostridium difficile infection.
* Monitor serum magnesium levels, especially with prolonged use or concomitant use of digoxin or diuretics.
* Monitor bone mineral density with prolonged therapy.
* Monitor for signs of vitamin B12 deficiency with prolonged therapy.
## Clinical Pearls
* Administer oral pantoprazole at least 30 minutes before a meal.
* For IV administration, reconstitute and dilute as per manufacturer instructions. Infuse over 2 minutes.
* Long-term use of PPIs is associated with increased risk of fractures, C. difficile infection, hypomagnesemia, and vitamin B12 deficiency. Consider the risks and benefits for long-term therapy.
* Pantoprazole can mask symptoms of gastric malignancy.
***
*Disclaimer: This information is intended for healthcare professionals and does not replace a thorough review of the current prescribing information and relevant literature. Always verify current drug information before making clinical decisions.*
